Skip to main content
. Author manuscript; available in PMC: 2022 Apr 18.
Published in final edited form as: Ann Pancreat Cancer. 2020 Jun 2;3:6. doi: 10.21037/apc.2020.03.02

Table 1.

Examples of homologous recombination deficiency (HRD) scores discovered and presented in the literature

Signature/algorithm name Description & features Reference
Myriad’s MyChoice HRD Tested in ovarian tumors and 57 cell lines (breast and pancreatic) (22)
Association between homologous recombination defects and genomic patterns of loss of heterozygosity (LOH)
The HRD score appears capable of detecting homologous recombination defects regardless of etiology or mechanism
Single Base Substitution Signatures (SBS3) Analysis of 7,042 cancers lead to more than 20 distinct mutational signatures (18)
SBS3 signature observed in breast, ovarian and pancreatic tumors showed association with BRA1/2 mutations
SBS3 is characterized by large deletions (up to 50 bp) with overlapping microhomology at breakpoint junctions
HRD gene signature Based on transcriptional profiling approach to systematically identify common molecular changes associated with defective HR repair (29)
Tested on isogenic cell lines established from MCF-10A cells, an immortal human mammary epithelial cell line of nonmalignant origin, with induced deficiency individually in HR repair genes: BRCA1, RAD51 and BRIT1 and other
HRD gene signature allows interrogation of the status of HR repair by simultaneously considering hundreds of genes and thereby allows identification of HR deficiency in a given cellular state independent of underlying mechanism
Waddell structural variations load subtyping Based on whole genome sequencing (WGS) and copy number variation (CNV) analysis of 100 pancreatic ductal adenocarcinomas (PDAC) tumors (30)
Patterns of chromosomal structural variations/rearrangements classified PDACs into 4 subtypes with potential clinical utility: stable, locally rearranged, scattered and unstable
Genomic instability co-segregated with inactivation of DNA maintenance genes (BRCA1, BRCA2 or PALB2) and a mutational signature of DNA damage repair deficiency
Double strand break repair signature (DSBR) Based on whole genome & RNA sequencing on 160 PDAC cases from 154 patients in the discovery cohort and WGS of 95 samples in the replication cohort (25)
Analyses of mutational signatures based on Alexandrov approach identified 4 PDAC principal subtypes: (I) an age-related group dominated by signatures 1 and 5, (II) a double-strand break repair (DSBR) group characterized by signature 3, attributed to deficiencies in homologous recombination repair (HRR) of double-strand breaks; (III) a mismatch repair (MMR) group characterized by signatures 6, 20, and 26, attributed to defects in DNA MMR; and (4) a group characterized by signature 8, of unknown etiology
DSBR &MMR subtypes were associated with increased expression of antitumor immunity, including activation of CD8-positive T lymphocytes and overexpression of regulatory molecules (CTL4), corresponding to higher frequency of somatic mutations and tumor-specific neoantigens
HRDetect score Based on lasso logistic regression model to identify six distinguishing mutational signatures predictive of BRCA1/BRCA2 deficiency (31)
Tested in 560 individuals with breast cancer and validated on independent cohorts of breast, ovarian and pancreatic cancers
Shows high sensitivity (98.7%) in identification of BRCA1/2 deficient tumors